Cabozantinib Therapy In Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is a predominant form of liver cancer, accounting for approximately 90% of cases. Unfortunately, it carries a grim prognosis, with a median survival rate ranging from 6 to 18 months. Historically, sorafenib had been the established first-line therapy for HCC. However, in recent
Tag: hepatocellular carcinoma
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers Overview In a retrospective multi-center study involving 747 patients with advanced hepatocellular carcinoma (HCC) treated with a combination therapy of atezolizumab and bevacizumab, the influence of butyric acid-producing enterobacteria on treatment outcomes was investigated. Previous research has established a link between the gut
